Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLF) Short Interest Up 21.8% in August

Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLF) was the target of a large growth in short interest in the month of August. As of August 31st, there was short interest totalling 6,269,500 shares, a growth of 21.8% from the August 15th total of 5,149,100 shares. Based on an average daily volume of 200 shares, the days-to-cover ratio is presently 31,347.5 days.

Ono Pharmaceutical Price Performance

OPHLF stock remained flat at $15.50 during midday trading on Monday. Ono Pharmaceutical has a 52 week low of $12.66 and a 52 week high of $19.39. The stock’s fifty day moving average is $14.08 and its two-hundred day moving average is $14.78.

Ono Pharmaceutical (OTCMKTS:OPHLF) last posted its earnings results on Wednesday, July 31st. The company reported $0.34 EPS for the quarter. The firm had revenue of $754.85 million during the quarter. Ono Pharmaceutical had a return on equity of 14.95% and a net margin of 24.26%. As a group, equities analysts anticipate that Ono Pharmaceutical will post 1.44 earnings per share for the current fiscal year.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia.